We track 21 organisations in this sector across 6+ countries.
21 entries.
Organizes executive education courses focused on leading the bio-revolution across life science sectors. Based in Lyngby, Denmark, ELPIS offers leadership development programs for biotech and pharma professionals, bringing together industry executives, researchers, and entrepreneurs to discuss commercialization strategies and emerging trends in biotechnology.
Emma Johnson is Senior Principal at M Ventures, the corporate venture capital arm of Merck KGaA, one of the world's leading science and technology companies. Based in the Netherlands, M Ventures invests globally in life sciences, healthcare, and biotechnology, and Emma focuses on identifying and supporting early- to mid-stage biotech companies across Europe and beyond. She is an active participant in the European life science VC ecosystem.
Ester Sklarsky is Principal at Sound Bioventures, a Nordic life science venture capital firm specializing in early-stage biotechnology, pharmaceutical, and medtech companies in Scandinavia and the broader European region. She is an active investor and participant in the Nordic life science investment community. Sound Bioventures is one of the leading dedicated life science VCs focused on the Nordic ecosystem.
FAST is a non-profit organization founded in 2017 by Ruben Vardanyan, Noubar Afeyan, and partners, with the mission to build a research and innovation ecosystem in Armenia across AI and data science, advanced materials, biotechnology, and robotics. It has funded over 260 researchers, supported more than 800 entrepreneurs, and backed 35+ startups through grants, acceleration, and a university-linked education-research-commercialisation model.
Gunilla Osswald is CEO of BioArctic AB, a Swedish biotechnology company focused on neurodegenerative diseases including Alzheimer's and Parkinson's disease. BioArctic co-developed lecanemab, marketed as Leqembi, a groundbreaking amyloid-targeting antibody therapy approved for early Alzheimer's disease in partnership with Eisai. She is one of the most prominent biotech executives in the Nordic region, leading a company that achieved a major therapeutic milestone.
HealthCap is one of Europe's largest dedicated life science venture capital firms, headquartered in Stockholm, Sweden. Founded in 1997, the firm invests in biotech, pharmaceutical, and medical device companies across the Nordic region and internationally. HealthCap has backed numerous successful life science companies over more than two decades and manages multiple funds with a strong track record in European biotech.
Jessica Martinsson is Director General and CEO of SwedenBIO, Sweden's national trade association for the life science sector representing biotech, pharmaceutical, and medtech companies. She leads the organization that owns and produces Nordic Life Science Days, the largest partnering event in the Nordic life science industry. She advocates for Swedish life science competitiveness and innovation policy at national and EU levels.
Kevin Dalgaard is Senior Principal at Lundbeckfonden BioCapital, the venture capital investment arm of the Lundbeck Foundation, one of Denmark's largest private foundations dedicated to advancing research in brain and neurological diseases. He evaluates and manages life science investments across the Nordic and global biotech ecosystems. Lundbeckfonden BioCapital is a key and highly respected institutional investor in the Scandinavian life science community.
Kristina Ekberg is Partner at HealthCap, one of Europe's largest dedicated life science venture capital firms, headquartered in Stockholm, Sweden. She focuses on biotech and pharmaceutical investments in the Nordic region and beyond. HealthCap has been one of the most active life science investors in Scandinavia for more than two decades, managing multiple funds with a strong track record of exits.
Course designed to equip leaders with insights and strategies for navigating and driving innovation in the life science bio-revolution. Focuses on emerging trends and leadership challenges in the sector.
Maha Radhakrishnan, MD, is Executive Partner at Sofinnova Investments, one of Europe's leading dedicated life science venture capital firms. A physician-scientist by training, she brings deep expertise in biopharmaceuticals and drug development to evaluating and supporting therapeutic companies across oncology, rare diseases, and CNS disorders. She is a prominent investor and speaker in the European and global biotech ecosystem.
Malta Life Sciences Park (MLSP) is a 13,500 sqm facility in San Gwann providing laboratories, offices, meeting rooms, and shared infrastructure to life sciences, biotechnology, and healthcare IT companies at all stages from startup to established enterprise. Built with EU regional development funds and opened in 2015, it serves as the national focal point for R&D in the life sciences sector and is co-located near the University of Malta and the main government hospital.
Nasekomo is a Bulgarian agtech company founded in 2017 that produces sustainable protein and organic fertiliser by farming Black Soldier Flies. The company converts agricultural by-products and organic waste into insect-derived animal feed ingredients using AI-assisted bioconversion processes. It raised €8 million in a Series A round in January 2024, backed by Invenio Partners, to scale its robotised production and franchise model internationally.
Niklas Blomberg is Executive Director of the Innovative Health Initiative (IHI), a major public-private partnership joint undertaking established by the European Union and EFPIA with approximately €2 billion in funding for health research and innovation. He oversees one of Europe's most significant health R&D programmes, bridging academia, industry, regulators, and patient organisations. He is a key figure in European health innovation policy and ecosystem building.
Sound Bioventures is a Nordic life science venture capital firm investing in early-stage biotechnology, pharmaceutical, and medical technology companies in Scandinavia and the Baltic region. The firm focuses on science-driven innovation in therapeutics and diagnostics and is an active sponsor of the Nordic life science community. It served as Investor Dinner Sponsor at Nordic Life Science Days 2026.
Stina Wallmark is Investment Director for Life Sciences at Voima Ventures, a leading Finnish venture capital firm investing in deep technology and life sciences startups. She focuses on early-stage science-based companies in the Nordic and Baltic region. Voima Ventures is recognized as one of Finland's most active investors in transformative science-based innovation across health, biology, and materials.
SwedenBIO is Sweden's national trade and interest organization for the life science industry, representing biotechnology, pharmaceutical, and medtech companies. Through its commercial arm SwedenBIO Service AB, it owns and produces Nordic Life Science Days (NLSDays), the largest Nordic partnering event for the life sciences sector. The organization advocates for Swedish life science competitiveness, innovation policy, and industry development at national and international levels.
Tartu Biotehnoloogiapark (BioPark) is a business and science park located in Tartu, Estonia, providing physical infrastructure and business development services to companies and research institutions in biotechnology, medicine, and health technology. BioPark is the primary organizer of the Estonian HealthTech Week, an annual gathering of health innovators, researchers, policymakers, and entrepreneurs from the Baltic Sea region and beyond.
TS Ventures is the first corporate venture capital fund established in the Western Balkans, launched in 2021 by Telekom Srbija with a €25 million mandate to invest in high-tech startups across pre-seed through growth stages. Headquartered in Belgrade at Milutina Milankovića 3v, the fund backs companies in AI, biotechnology, and digital platforms, with a particular interest in transformative technologies that can scale regionally and globally. The fund has deployed approximately €2.4 million across 15+ startups, with an average ticket size of €133,000. Notable investments include AI-driven professional networking platform Connect The Dots and biotech firm LampoVet.
Victor Decrion is Managing Partner at Lauxera Capital Partners, a European venture capital firm specializing in cardiovascular disease therapeutics and cardiometabolic drug development. He is a notable life science investor active in the European and Nordic biotech partnering ecosystem. Lauxera Capital is recognized for its focused thesis in cardiovascular innovation, an underserved area in European life science VC.
Zoë Johnson heads Gubra Ventures as Head of Ventures at Gubra, a Danish bioscience company focused on metabolic diseases and CNS disorders. Gubra Ventures is the investment and partnering arm of Gubra, providing capital and expertise to early-stage biotech companies aligned with Gubra's scientific areas. She is an active investor and connector in the Nordic and European life science ecosystem.